TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8559495
Drug: Antiplatelet drugs
Normalized name: simethicone
DrugBank: Simethicone (DB09512)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiplatelet drugs (ditazole, ticlopidine, aspirin plus dipyridamole)
Study: 8559495
Drug: No antiplatelet
Approvals — FDA: no, EMA: no, PMDA: no
Description: No antiplatelet drugs
Study: 8559495
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (uraemic patients not on rHuEpo therapy)
Study: 7419011
Drug: Intravenous fat
Normalized name: Hard fat
DrugBank: Hard fat (DB11578)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous fat (20 g of Intralipid)
Study: 7419011
Drug: Intraduodenal fat
Normalized name: Hard fat
DrugBank: Hard fat (DB11578)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraduodenal fat (20 g of Intralipid)
Study: 7419011
Drug: Intravenous amino
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous amino acids (21 g L‐amino acids; Freamine II) plus glucose (50 g)
Study: 30776476
Drug: Omega-3 fatty
Normalized name: Omega-3 fatty acid
DrugBank: Omega-3 fatty acids (DB11133)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omega-3 fatty acids (1800 mg containing 1206 mg EPA) for 12 weeks
Study: 30640652
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg of perineural dexamethasone
Study: 30640652
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg of perineural dexamethasone
Study: 30640652
Drug: 8 mg
Normalized name: alloin 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 mg of perineural dexamethasone
Study: 23524017
Drug: Supratherapeutic doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supratherapeutic doses of salbutamol (SALB) 200 μg (3 doses at 20 min intervals)
Study: 23524017
Drug: Supratherapeutic doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supratherapeutic doses of ipratropium bromide (IPR) 20 μg, 20 μg, and 40 μg (at 20 min intervals)
Study: 23524017
Drug: Supratherapeutic doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supratherapeutic doses of salbutamol (SALB) 200 μg (3 doses at 20 min intervals) after MABA 1200
Study: 23524017
Drug: Supratherapeutic doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supratherapeutic doses of ipratropium bromide (IPR) after MABA 1200
Study: 19515536
Drug: Extended release
Normalized name: Tylenol Extended Release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended release MET (500 to 1000 mg daily)
Study: 11499332
Drug: Oral terbinafine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral terbinafine 250 mg once daily for 2 or 4 weeks
Study: 8159103
Drug: Dilevalol 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dilevalol 400 mg x 1
Study: 8159103
Drug: Metoprolol succinate
Normalized name: Metoprolol Succinate
DrugBank: Metoprolol (DB00264)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Metoprolol succinate 200 mg x 1
Study: 29343998
Drug: Continuous positive
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous positive airway pressure therapy
Study: 29689045
Drug: Parenting group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenting group intervention (visits by child development agents and fortnightly meetings)
Study: 26755466
Drug: Cognitive-existential group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-existential group therapy (12 sessions of 90 minutes twice per week)
Study: 22584916
Drug: CD4-guided planned
Normalized name: levonorgestrel
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: CD4-guided planned treatment interruptions (PTIs)
Study: 21358200
Drug: Finafloxacin 200
Normalized name: Finafloxacin
DrugBank: Finafloxacin (DB09047)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Finafloxacin 200 mg
Study: 21358200
Drug: Finafloxacin 800
Normalized name: Finafloxacin
DrugBank: Finafloxacin (DB09047)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Finafloxacin 800 mg
Study: 8833554
Drug: PCA morphine:
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCA morphine: 1 mg with 6-minute lockout
Study: 8833554
Drug: PCACI: PCA
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCACI: PCA morphine 1 mg with 6-minute lockout plus 0.5-1 mg/h continuous infusion
Study: 1558438
Drug: Theophylline treatment
Normalized name: Theophylline
DrugBank: Theophylline (DB00277)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Theophylline treatment (oral, 7 days, plasma level 87.7 +/‐ 7.8 mumol/L)
Study: 25141137
Drug: 10-day levofloxacin-containing
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10-day levofloxacin-containing triple therapy (levofloxacin 500 mg once daily, amoxicillin 1 g twice daily, esomeprazole 40 mg twice daily)
Study: 25141137
Drug: 14-day levofloxacin-containing
Approvals — FDA: no, EMA: no, PMDA: no
Description: 14-day levofloxacin-containing triple therapy (levofloxacin 500 mg once daily, amoxicillin 1 g twice daily, esomeprazole 40 mg twice daily)
Study: 25141137
Drug: 10-day levofloxacin-containing
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10-day levofloxacin-containing triple therapy (levofloxacin 500 mg once daily) with levofloxacin-susceptible strains
Study: 25141137
Drug: 10-day levofloxacin-containing
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10-day levofloxacin-containing triple therapy (levofloxacin 500 mg once daily) with levofloxacin-resistant strains
Study: 25141137
Drug: 14-day levofloxacin-containing
Approvals — FDA: no, EMA: no, PMDA: no
Description: 14-day levofloxacin-containing triple therapy (levofloxacin 500 mg once daily) with levofloxacin-susceptible strains
Study: 25141137
Drug: 14-day levofloxacin-containing
Approvals — FDA: no, EMA: no, PMDA: no
Description: 14-day levofloxacin-containing triple therapy (levofloxacin 500 mg once daily) with levofloxacin-resistant strains
Study: 11788212
Drug: Intravenous followed
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous followed by oral conjugated estrogen for 21 days
Study: 11788212
Drug: Intravenous estrogen
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous estrogen followed by oral conjugated estrogen plus medroxyprogesterone for 21 days
Study: 2111627
Drug: Nalbuphine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nalbuphine (10 mg)
Study: 27466224
Drug: 3 mL
Normalized name: WATER,INHL 3 ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mL Hyaluronic Acid (HA) injection
Study: 27466224
Drug: 3 mL
Normalized name: WATER,INHL 3 ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mL saline solution (placebo)
Study: 17044900
Drug: Oral baclofen
Normalized name: Baclofen
DrugBank: Baclofen (DB00181)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral baclofen
Study: 10545429
Drug: Accelerated alteplase
Normalized name: Alteplase
DrugBank: Alteplase (DB00009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Accelerated alteplase (100 mg/90 min; n=21)
Study: 10545429
Drug: Conventional alteplase
Normalized name: Alteplase
DrugBank: Alteplase (DB00009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conventional alteplase (100 mg/180 min; n=15)
Study: 6318350
Drug: Bi‐Profenid 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bi‐Profenid 150 mg (one 150 mg tablet twice daily for 2 days)
Study: 6318350
Drug: Conventional forms
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional forms (two 50 mg Profenid capsules each morning and noon with one 100 mg suppository each evening for 2 days)
Study: 31835978
Drug: Platelet transfusion
Normalized name: platelet glycoprotein VI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Platelet transfusion during rewarming phase (10 mL/kg)
Study: 24443618
Drug: trastuzumab-based chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: trastuzumab-based chemotherapy
Study: 17412737
Drug: Infliximab 3
Normalized name: Infliximab
DrugBank: Infliximab (DB00065)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Infliximab 3 mg/kg at weeks 0, 2, 6, 14 and 22
Study: 10963245
Drug: Self-management of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-management of oral anticoagulant therapy
Study: 8640434
Drug: No intracameral
Approvals — FDA: no, EMA: no, PMDA: no
Description: No intracameral antibiotics (control group)
Study: 1531090
Drug: Prednisolone (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisolone (40 mg per day for 28 days)
Study: 6323525
Drug: Antibody to
Normalized name: Antibody to HPA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibody to gD and vp66
Study: 29239664
Drug: SR paracetamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: SR paracetamol 2×1000 mg BID
Study: 20116153
Drug: Dialysis dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dialysis dose
Study: 11109233
Drug: Imagery-rehearsal therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imagery-rehearsal therapy (treatment group)
Study: 8845036
Drug: Oral vaccination
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral vaccination with whole cell/B subunit (CTB) cholera vaccine
Study: 8845036
Drug: Local intravaginal
Normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local intravaginal vaccination with whole cell/B subunit (CTB) cholera vaccine mixed with eldexomer gel
Study: 1341234
Drug: Group B:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group B: approximately 3.0 g d‐1 sodium sulphate in juice
Study: 1341234
Drug: Group C:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group C: 30 g d‐1 supplementary dietary fibre as wheat bran in bread
Study: 22891797
Drug: N-acetyl cysteine
Normalized name: N-Acetyl Cysteine
Approvals — FDA: no, EMA: no, PMDA: no
Description: N-acetyl cysteine (NAC) 2 g/day as adjunct maintenance treatment
Study: 20378080
Drug: Mipomersen 200
Normalized name: mipomersen 200 mg/mL subcutaneous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mipomersen 200 mg/week
Study: 21593041
Drug: Mipomersen 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mipomersen 300 mg/week
Study: 17094172
Drug: Water extract
Normalized name: Panax ginseng root water extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Water extract of Hibiscus sabdariffa (300 mL daily for 3 days)
Study: 18598992
Drug: Conventional treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatments with distal colonoscopy
Study: 18598992
Drug: Anti-viral treatment
Normalized name: Anti Bac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-viral treatment added to conventional treatments
Study: 9362378
Drug: IL-2 treatment
Normalized name: miconazole
DrugBank: Miconazole (DB01110)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: IL-2 treatment overall
Study: 11915784
Drug: HIGH CHO
Normalized name: High choriolytic enzyme
Approvals — FDA: no, EMA: no, PMDA: no
Description: HIGH CHO diet (greater than 70% of daily energy intake from CHO)
Study: 11915784
Drug: LOW CHO
Normalized name: Low choriolytic enzyme
Approvals — FDA: no, EMA: no, PMDA: no
Description: LOW CHO diet (less than 10% of daily energy intake from CHO)
Study: 21831359
Drug: Paliperidone ER
Normalized name: Paliperidone ER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paliperidone ER (6 mg)
Study: 22585590
Drug: Risperidone (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risperidone (3 mg)
Study: 17376267
Drug: Rhubarb preventive
Normalized name: RHUBARB
DrugBank: Rhubarb (DB10651)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rhubarb preventive treatment group (3.0%)
Study: 17376267
Drug: Enteral combined
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enteral combined parenteral nutrition support subgroup (2.1%)
Study: 17376267
Drug: Parenteral nutrition
Normalized name: parenteral nutrition solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral nutrition support subgroup
Study: 12030958
Drug: Double dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double dose of proton pump inhibitor
Study: 12030958
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of proton pump inhibitor
Study: 2189319
Drug: New formulation
Normalized name: TRIPROLIDINE HYDROCHLORIDE 1.25 mg in 1 mL ORAL SYRUP [HISTEX PD Drops New Formulation]
Approvals — FDA: no, EMA: no, PMDA: no
Description: New formulation of intranasal flunisolide (0.025% solution, 200 micrograms daily for 4 weeks)
Study: 2189319
Drug: Original formulation
Normalized name: Zegerid (Original Formulation)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Original formulation of intranasal flunisolide (0.025% solution, 200 micrograms daily for 4 weeks)
Study: 2189319
Drug: New formulation
Normalized name: TRIPROLIDINE HYDROCHLORIDE 1.25 mg in 1 mL ORAL SYRUP [HISTEX PD Drops New Formulation]
Approvals — FDA: no, EMA: no, PMDA: no
Description: New formulation of intranasal flunisolide
Study: 2189319
Drug: Original formulation
Normalized name: Zegerid (Original Formulation)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Original formulation of intranasal flunisolide
Study: 43164
Drug: Atenolol (138
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol (138 +/- 13 mg daily)
Study: 43164
Drug: Metoprolol (234
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol (234 +/- 22 mg daily)
Study: 43164
Drug: Pindolol (24
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pindolol (24 +/- 2 mg daily)
Study: 43164
Drug: Labetalol (308
Approvals — FDA: no, EMA: no, PMDA: no
Description: Labetalol (308 +/- 34 mg daily)
Study: 30777131
Drug: High-dose Interleukin-2
Normalized name: Interleukin-2 aldesleukin
DrugBank: Aldesleukin (DB00041)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: High-dose Interleukin-2 (HD IL-2)
Study: 17432678
Drug: Shenfu Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shenfu Injection (SF) 1 mL/kg
Study: 17432678
Drug: Shenfu Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shenfu Injection (SF)
Study: 14571614
Drug: Luohuo Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Luohuo Capsule (LHC)
Study: 8804239
Drug: Subcutaneous (s.c.)
Normalized name: immune globulin subcutaneous (human) - klhw Injection [Xembify]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous (s.c.) recombinant erythropoietin (rH-EPO)
Study: 8804239
Drug: Intravenous (i.v.)
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (i.v.) recombinant erythropoietin (rH-EPO)
Study: 6376918
Drug: Low-phosphorus, low-protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-phosphorus, low-protein diet (7.0 mg phosphorus and 0.5 g protein per kg body weight)
Study: 6376918
Drug: Control diet
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control diet (12 mg phosphorus and 0.8 g protein per kg body weight)
Study: 29573473
Drug: Romosozumab 210
Normalized name: ROMOSOZUMAB
DrugBank: Romosozumab (DB11866)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Romosozumab 210 mg s.c. once monthly for 12 months
Study: 24774860
Drug: Calcitriol supplementation
Normalized name: Calcitriol
DrugBank: Calcitriol (DB00136)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcitriol supplementation (0.5 μg/day for one year)
Study: 17920715
Drug: Hyperfractionated radiotherapy
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hyperfractionated radiotherapy (HF) - 58 Gy in 40 equal fractions given twice per day
Study: 17920715
Drug: Conventional fractionation
Normalized name: LIVER FRACTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional fractionation (CF) - 51 Gy in 20 equal daily fractions
Study: 16033855
Drug: Short daily
Normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short daily hemodialysis (6 sessions/wk of 3 h each)
Study: 12241539
Drug: Noradrenaline infusion
Normalized name: noradrenaline hydrochloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Noradrenaline infusion (0.147 nmol.min(‐1).kg(‐1))
Study: 12241539
Drug: Emagel infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Emagel infusion (control)
Study: 9737807
Drug: Troglitazone 400
Normalized name: troglitazone 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Troglitazone 400 mg once daily
Study: 9737807
Drug: Troglitazone 200
Normalized name: troglitazone 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Troglitazone 200 mg twice daily
Study: 9737807
Drug: Troglitazone 800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Troglitazone 800 mg once daily
Study: 9737807
Drug: Troglitazone 400
Normalized name: troglitazone 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Troglitazone 400 mg twice daily
Study: 25239484
Drug: 0.5 mL
Normalized name: ethanol 0.5 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mL vaccine subcutaneously at days 0, 14
Study: 25239484
Drug: 0.5 mL
Normalized name: ethanol 0.5 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mL vaccine subcutaneously at days 0 and 28
Study: 25239484
Drug: 0.5 mL
Normalized name: ethanol 0.5 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mL vaccine subcutaneously at days 0, 14, and 28
Study: 25239484
Drug: 0.25 mL
Normalized name: mineral oil 0.25 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25 mL vaccine subcutaneously at days 0, 14, and 28
Study: 22348304
Drug: Diclofenac suppository
Normalized name: diclofenac Rectal Suppository
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac suppository (100 mg) plus saline 0.9% (placebo)
Study: 22348304
Drug: Diclofenac suppository
Normalized name: diclofenac Rectal Suppository
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac suppository (100 mg) plus intravenous papaverine hydrochloride (1.5 mg/kg up to 120 mg)
Study: 11896091
Drug: Soy beverage
Normalized name: soy acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soy beverage containing 90 mg of isoflavones
Study: 9808483
Drug: Daily oral
Normalized name: GEMTESA 75 MG Once-Daily Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily oral clodronate (800 mg)
Study: 9808483
Drug: Daily intranasal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily intranasal calcitonin (200 IU)
Study: 2521333
Drug: Furosemide (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Furosemide (5 mg i.v. bolus)
Study: 7262760
Drug: Lidaprim (combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidaprim (combination of sulfametrol and trimethoprim)
Study: 30678256
Drug: Mother’s own
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mother’s own milk (MOM) supplements of preterm formula
Study: 28914247
Drug: Nitrous oxide
Normalized name: Nitrous Oxide
DrugBank: Nitrous oxide (DB06690)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nitrous oxide (N2O)‐oxygen (O2) inhalation sedation using preadjusted mix of 30% N2O and 70% O2 through rapid induction technique
Study: 27128005
Drug: Extemporaneous preparation
Normalized name: Extemporaneous preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extemporaneous preparation suspension (EP; 10 mg/mL)
Study: 27128005
Drug: Crushed sildenafil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crushed sildenafil 20 mg tablet mixed with apple sauce
Study: 27128005
Drug: Intact sildenafil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intact sildenafil 20 mg tablet
Study: 23628755
Drug: Manual therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manual therapy and exercise (MTEX)
Study: 22480173
Drug: Resection of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resection of the primary tumour prior to systemic chemotherapy
Study: 22480173
Drug: Systemic chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic chemotherapy without resection of the primary tumour
Study: 19365388
Drug: Cymbalta (antidepressant,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cymbalta (antidepressant, serotonin and noradrenalin reuptake inhibitor)
Study: 17689883
Drug: Short-term androgen
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Short-term androgen deprivation (STAD) + radiation therapy (RT)
Study: 9581695
Drug: Thymosin alpha1
Normalized name: Thymosin alpha1 (human)
DrugBank: Thymalfasin (DB04900)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thymosin alpha1 (Talpha) 1.6 mg subcutaneous injection two times a week for 26 weeks (T6 group)
Study: 9581695
Drug: Thymosin alpha1
Normalized name: Thymosin alpha1 (human)
DrugBank: Thymalfasin (DB04900)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thymosin alpha1 (Talpha) 1.6 mg subcutaneous injection two times a week for 52 weeks (T12 group)
Study: 9581695
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (T0 group) followed up for 18 months without specific treatment
Study: 8114857
Drug: Low-protein diet
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-protein diet (1.3 or 0.58 g of protein per kg per day)
Study: 8114857
Drug: Very-low-protein diet
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Very-low-protein diet (0.28 g per kg per day)
Study: 8114857
Drug: Low-protein diet
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-protein diet (0.58 g per kg per day)
Study: 3404450
Drug: Ultra-low yield
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultra-low yield cigarettes (0.1, 0.4, 0.7 mg nicotine)
Study: 3404450
Drug: Usual-brand high-yield
Normalized name: Eagle Brand Medicated Oil
DrugBank: Eucalyptus oil (DB11114)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual-brand high-yield cigarettes (1.0, 1.1 mg nicotine)
Study: 28776320
Drug: New Medicine
Approvals — FDA: no, EMA: no, PMDA: no
Description: New Medicine Service (NMS)
Study: 26071796
Drug: Tigatuzumab (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tigatuzumab (6 mg/kg loading, 2 mg/kg/week maintenance) plus sorafenib 400 mg twice daily
Study: 26071796
Drug: Tigatuzumab (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tigatuzumab (6 mg/kg loading, 6 mg/kg/week maintenance) plus sorafenib 400 mg twice daily
Study: 23924691
Drug: Black soy
Normalized name: soy acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Black soy peptide supplementation (4.5 g daily for 8 weeks)
Study: 21650086
Drug: 250 mg
Normalized name: rutin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg ascorbic acid (Vit. C)
Study: 19526424
Drug: Nicotine patch
Normalized name: Nicotine Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine patch (15 mg/16 h)
Study: 19526424
Drug: Nasal spray
Normalized name: Nasal Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal spray (recommended regimen of 24 doses per day)
Study: 16946104
Drug: R406 (spleen
Approvals — FDA: no, EMA: no, PMDA: no
Description: R406 (spleen tyrosine kinase inhibitor)